Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse MKT  >  Asterias Biotherapeutics Inc    AST

ASTERIAS BIOTHERAPEUTICS INC (AST)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Asterias Biotherapeutics : Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2018 | 10:45am CEST

Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and cell-based therapeutics to treat neurological conditions associated with demyelination, today announced that the Safety Review Committee (SRC) for the first clinical trial of AST-VAC2, held a scheduled meeting to review the safety and tolerability data generated in the first patient enrolled in the study and recommended continuation of the study and moving to parallel enrollment of the second and third patients in the advanced cancer cohort (Arm A), as planned per the studys protocol. This initial clinical trial, which is being sponsored, managed and funded by Cancer Research UK under a collaboration between Asterias and Cancer Research UK, will examine the safety and tolerability of AST-VAC2 in non-small cell lung cancer (NSCLC) as the studys primary endpoints. Secondary and tertiary endpoints of the study include evaluations of the immunogenicity of AST-VAC2 in NSCLC.

"Based on its review of all available study data after five doses in the first patient, the Safety Review Committees recommendation to continue the trial without modification reaffirms our belief that AST-VAC2 is safe and well-tolerated," commented Dr Edward Wirth, Chief Medical Officer of Asterias Biotherapeutics. The committee concluded that the trial can proceed as planned per protocol - an important step as we continue the clinical development of AST-VAC2."

The Safety Review Committee reviewed all of the accumulated safety data generated to date for the first patient in Arm A (advanced disease), who by the time of the review had received five, weekly doses of 10 million AST-VAC2 cells.

As specified in the AST-VAC2 clinical trial protocol, the Safety Review Committee meets on a dosing-driven basis to review safety and tolerability data from the ongoing trial. The committee is comprised of a group of medical and scientific experts and is responsible for reviewing and evaluating patient safety data in order to safeguard the wellbeing of trial participants.

(c) 2018 Gulf Sports Media All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTERIAS BIOTHERAPEUTICS I
09/25BioTime Warrants to Expire on October 1, 2018
AQ
09/21ASTERIAS BIOTHERAPEUTICS : FDA Accepts Asterias Biotherapeutics Request to Meet ..
AQ
09/20BioTime Implements New Leadership Structure, Appoints Brian Culley as Chief E..
AQ
09/20FDA Accepts Asterias Biotherapeutics’ Request to Meet and Discuss Next ..
GL
09/19BioTime Updates Timeline for Distribution of AgeX Shares to BioTime Sharehold..
AQ
09/18ASTERIAS BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form..
AQ
09/14ASTERIAS BIOTHERAPEUTICS : Provides 24 Month Cohort 2 Update for its OPC1 Phase ..
AQ
09/12ASTERIAS BIOTHERAPEUTICS : Provides 24 Month Cohort 2 Update for its OPC1 Phase ..
AQ
09/06ASTERIAS BIOTHERAPEUTICS : Patent Issued for Screening Methods For Human Embryon..
AQ
09/06ASTERIAS BIOTHERAPEUTICS : Announces Positive Outcome from Second Safety Review ..
AQ
More news
News from SeekingAlpha
09/20FDA accepts Asterias Biotherapeutics? Type B request for OPC1 spinal cord inj.. 
09/04Asterias up 3% after second safety review of VAC2 study 
08/10Asterias Biotherapeutics, Inc. (AST) CEO Mike Mulroy on Q2 2018 Results - Ear.. 
08/09Asterias Biotherapeutics misses by $0.03, misses on revenue 
07/193 THINGS IN BIOTECH, JULY 19 : Karyopharm Rolls Out, And Cellectar Looks To Keep.. 
Financials ($)
Sales 2018 0,78 M
EBIT 2018 -21,6 M
Net income 2018 -20,1 M
Finance 2018 23,8 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 68,8x
EV / Sales 2019 77,7x
Capitalization 77,7 M
Chart ASTERIAS BIOTHERAPEUTICS INC
Duration : Period :
Asterias Biotherapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 9,50 $
Spread / Average Target 579%
EPS Revisions
Managers
NameTitle
Michael H. Mulroy President, Chief Executive Officer & Director
Don Matthew Bailey Non-Executive Chairman
Ryan D. Chavez CFO, Secretary & General Counsel
Edward D. Wirth Chief Medical Officer
Craig Halberstadt Senior VP-Research & Product Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTERIAS BIOTHERAPEUTICS INC-40.00%78
CELLTRION, INC.--.--%33 911
IQVIA HOLDINGS INC32.60%26 045
LONZA GROUP18.19%23 979
INCYTE CORPORATION-30.46%14 132
SEATTLE GENETICS, INC.49.29%12 470